Samsung Bioepis Announces Approval of Ustekinumab Biosimilar in Japan

Ustekinumab BS Subcutaneous Injection 45mg Syringes ‘NIPRO’ has been granted marketing approval in Japan
First marketing approval under the partnership with NIPRO CORPORATION, paving the way for expanding treatment option for patients in Japan
‘NIPRO’ will be commercially available following its listing on the National Health Insurance (NHI) drug price list in May 2026

• 페북
• 트윗
• 카톡
• 기타